Sean McCarthy, CytomX CEO
November 17, 2022 08:27 AM ESTUpdated 08:43 AM
Deals

Re­gen­eron throws strug­gling Cy­tomX a life­line with $30M can­cer bis­pe­cif­ic deal

Max Gelman

Senior Editor

Re­gen­eron is team­ing up with a biotech that has strug­gled af­ter ax­ing its lead pro­gram just four months ago.

The big bio­phar­ma signed a li­cens­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

A service from the Financial Times